Who are Genetically attenuated PfSPZ Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Prevnar 20, Recombinant Human Papillomavirus Bivalent Vaccine, bOPV (three dose), polyvalent pneumococcal vaccine, IPV at 14 and fIPV at 22 weeks, RotaTeq.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/genetically-attenuated-pfspz-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Genetically attenuated PfSPZ Vaccine — Competitive Intelligence Brief

Genetically attenuated PfSPZ Vaccine (Genetically attenuated PfSPZ Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine. Area: Infectious Diseases.

phase 2 Vaccine Infectious Diseases Biologic Live · refreshed every 30 min

Target snapshot

Genetically attenuated PfSPZ Vaccine (Genetically attenuated PfSPZ Vaccine) — Sanaria Inc.. The Genetically attenuated PfSPZ Vaccine works by introducing a weakened form of the Plasmodium falciparum parasite to stimulate an immune response against malaria.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Genetically attenuated PfSPZ Vaccine TARGET	Genetically attenuated PfSPZ Vaccine	Sanaria Inc.	phase 2	Vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Recombinant Human Papillomavirus Bivalent Vaccine	Recombinant Human Papillomavirus Bivalent Vaccine	National Cancer Institute (NCI)	marketed	Prophylactic vaccine	Human papillomavirus types 16 and 18 (HPV-16, HPV-18)
bOPV (three dose)	bOPV (three dose)	Centers for Disease Control and Prevention	marketed	vaccine	Poliovirus types 1 and 3
polyvalent pneumococcal vaccine	polyvalent pneumococcal vaccine	Astellas Pharma Inc	marketed	Polysaccharide vaccine
IPV at 14 and fIPV at 22 weeks, RotaTeq	IPV at 14 and fIPV at 22 weeks, RotaTeq	Centers for Disease Control and Prevention	marketed	vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Vaccine class)

GlaxoSmithKline · 16 drugs in this class
Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
Pfizer · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Henogen · 3 drugs in this class
Pfizer Inc. · 2 drugs in this class
Sanofi · 2 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
BioNTech · 2 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Genetically attenuated PfSPZ Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/genetically-attenuated-pfspz-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab